NASDAQ:LIFE - aTyr Pharma Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.91 +0.04 (+4.60 %)
(As of 05/23/2018 03:17 AM ET)
Previous Close$0.88
Today's Range$0.88 - $0.96
52-Week Range$0.80 - $6.50
Volume833,700 shs
Average Volume145,857 shs
Market Capitalization$28.34 million
P/E Ratio-0.49
Dividend YieldN/A
Beta3.49

About aTyr Pharma (NASDAQ:LIFE)

aTyr Pharma logoaTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of medicines for the treatment of cancer and lung disease in the United States. The company's therapeutic candidate pipeline that includes ATYR1923 candidate, an agonist of the Resokine pathway that is in Phase I clinical trial designed to temper immune engagement in interstitial lung diseases; and ORCA program, a preclinical research stage program that targets immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. It is also developing ATYR1940, a therapeutic candidate based on a protein naturally secreted from muscle for the treatment of facioscapulohumeral muscular dystrophy, limb-girdle muscular dystrophy, and duchenne muscular dystrophy. aTyr Pharma, Inc. was founded in 2005 and is headquartered in San Diego, California.

Receive LIFE News and Ratings via Email

Sign-up to receive the latest news and ratings for LIFE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:LIFE
CUSIP53217V10
Phone858-731-8389

Debt

Debt-to-Equity Ratio0.24
Current Ratio6.90
Quick Ratio6.90

Price-To-Earnings

Trailing P/E Ratio-0.49
Forward P/E Ratio-0.77
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.16 per share
Price / Book0.42

Profitability

EPS (Most Recent Fiscal Year)($1.87)
Net Income$-48,200,000.00
Net MarginsN/A
Return on Equity-78.72%
Return on Assets-56.17%

Miscellaneous

Employees65
Outstanding Shares29,830,000

aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) posted its quarterly earnings data on Monday, March, 19th. The biotechnology company reported ($0.39) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.43) by $0.04. View aTyr Pharma's Earnings History.

When is aTyr Pharma's next earnings date?

aTyr Pharma is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for aTyr Pharma.

What price target have analysts set for LIFE?

4 brokerages have issued twelve-month price objectives for aTyr Pharma's stock. Their predictions range from $3.00 to $4.00. On average, they expect aTyr Pharma's stock price to reach $3.50 in the next twelve months. View Analyst Ratings for aTyr Pharma.

Who are some of aTyr Pharma's key competitors?

Who are aTyr Pharma's key executives?

aTyr Pharma's management team includes the folowing people:
  • Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 46)
  • Dr. Paul R. Schimmel, Founder & Director (Age 77)
  • Dr. David J. King, Chief Scientific Officer (Age 59)
  • Dr. John D. Mendlein, Strategic Advisor & Director (Age 58)
  • Dr. Sanuj K. Ravindran, Bus. Advisor (Age 46)

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

Has aTyr Pharma been receiving favorable news coverage?

News articles about LIFE stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. aTyr Pharma earned a media sentiment score of 0.06 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 45.92 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Who are aTyr Pharma's major shareholders?

aTyr Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Sofinnova Ventures Inc (6.26%) and Dimensional Fund Advisors LP (0.38%). Company insiders that own aTyr Pharma stock include Ashraf Amanullah, Ecor1 Capital Fund Qualified,, John Mendlein and Paul Schimmel. View Institutional Ownership Trends for aTyr Pharma.

Which major investors are buying aTyr Pharma stock?

LIFE stock was purchased by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc and Dimensional Fund Advisors LP. Company insiders that have bought aTyr Pharma stock in the last two years include Ashraf Amanullah, John Mendlein and Paul Schimmel. View Insider Buying and Selling for aTyr Pharma.

How do I buy shares of aTyr Pharma?

Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $0.91.

How big of a company is aTyr Pharma?

aTyr Pharma has a market capitalization of $28.34 million. The biotechnology company earns $-48,200,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. aTyr Pharma employs 65 workers across the globe.

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected]


MarketBeat Community Rating for aTyr Pharma (LIFE)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  329 (Vote Underperform)
Total Votes:  600
MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe LIFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

aTyr Pharma (NASDAQ:LIFE) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for aTyr Pharma in the last 12 months. Their average twelve-month price target is $3.50, suggesting that the stock has a possible upside of 284.62%. The high price target for LIFE is $4.00 and the low price target for LIFE is $3.00. There are currently 2 sell ratings, 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.752.002.002.25
Ratings Breakdown: 2 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.50$5.50$5.00$4.4625
Price Target Upside: 284.62% upside57.14% upside42.86% upside59.38% upside

aTyr Pharma (NASDAQ:LIFE) Consensus Price Target History

Price Target History for aTyr Pharma (NASDAQ:LIFE)

aTyr Pharma (NASDAQ:LIFE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2018CitigroupDowngradeNeutral ➝ SellHighView Rating Details
5/14/2018Piper Jaffray CompaniesReiterated RatingOverweight$3.00HighView Rating Details
2/14/2018JPMorgan ChaseDowngradeNeutral ➝ UnderweightHighView Rating Details
8/15/2017BMO Capital MarketsSet Price TargetHold$4.00HighView Rating Details
(Data available from 5/23/2016 forward)

Earnings

aTyr Pharma (NASDAQ:LIFE) Earnings History and Estimates Chart

Earnings by Quarter for aTyr Pharma (NASDAQ:LIFE)

aTyr Pharma (NASDAQ:LIFE) Earnings Estimates

2018 EPS Consensus Estimate: ($1.30)
2019 EPS Consensus Estimate: ($1.30)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.38)($0.36)($0.37)
Q2 20182($0.37)($0.30)($0.34)
Q3 20182($0.30)($0.27)($0.29)
Q4 20182($0.33)($0.28)($0.31)
Q1 20192($0.34)($0.29)($0.32)
Q2 20192($0.34)($0.30)($0.32)
Q3 20192($0.35)($0.31)($0.33)
Q4 20192($0.35)($0.32)($0.34)

aTyr Pharma (NASDAQ LIFE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/13/2018N/AView Earnings Details
5/14/2018Q1($0.35)($0.36)ViewListenView Earnings Details
3/19/2018Q4 2017($0.43)($0.39)ViewN/AView Earnings Details
11/14/2017Q3 2017($0.50)($0.43)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.57)($0.51)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.4970)($0.56)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.61)($0.53)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.67)($0.58)ViewN/AView Earnings Details
8/10/2016Q216($0.71)($0.65)ViewN/AView Earnings Details
5/11/2016Q1($0.70)($0.68)ViewN/AView Earnings Details
3/30/2016Q4($0.52)($0.70)ViewN/AView Earnings Details
11/10/2015Q3($0.48)($0.48)ViewN/AView Earnings Details
8/12/2015Q215($0.53)($0.74)ViewN/AView Earnings Details
6/18/2015Q115($0.41)($0.38)ViewN/AView Earnings Details
11/5/2013Q313$0.97$1.02$926.10 million$936.00 millionViewN/AView Earnings Details
7/31/2013Q2 2013$0.96$0.72$952.06 million$944.00 millionViewN/AView Earnings Details
5/2/2013Q1 2013$1.04$1.07$958.56 million$963.00 millionViewN/AView Earnings Details
2/4/2013Q4 2012$1.11$1.11$988.85 million$998.90 millionViewN/AView Earnings Details
11/1/2012Q312$0.89$0.92$907.91 million$911.00 millionViewN/AView Earnings Details
7/31/2012$0.97$0.96ViewN/AView Earnings Details
2/7/2012$1.04$1.06ViewN/AView Earnings Details
10/25/2011$0.88$0.94ViewN/AView Earnings Details
7/28/2011$0.95$0.89ViewN/AView Earnings Details
4/26/2011$0.85$0.85ViewN/AView Earnings Details
2/3/2011$0.87$0.90ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

aTyr Pharma (NASDAQ:LIFE) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

aTyr Pharma (NASDAQ LIFE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 25.00%
Institutional Ownership Percentage: 66.25%
Insider Trading History for aTyr Pharma (NASDAQ:LIFE)
Institutional Ownership by Quarter for aTyr Pharma (NASDAQ:LIFE)

aTyr Pharma (NASDAQ LIFE) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2018Paul SchimmelDirectorBuy150,000$1.00$150,000.00View SEC Filing  
5/16/2018Ecor1 Capital Fund Qualified,Major ShareholderSell3,209,316$0.93$2,984,663.88View SEC Filing  
2/8/2018Ashraf AmanullahInsiderSell1,402$3.40$4,766.80View SEC Filing  
8/31/2017John MendleinCEOBuy37,736$2.65$100,000.40View SEC Filing  
8/31/2017Paul SchimmelDirectorBuy94,336$2.65$249,990.4040,440View SEC Filing  
4/24/2017John MendleinCEOBuy124$3.00$372.00327,647View SEC Filing  
4/20/2017John MendleinCEOBuy2,552$3.00$7,656.00325,971View SEC Filing  
12/21/2016Paul SchimmelDirectorBuy25,000$2.28$57,000.0040,440View SEC Filing  
12/20/2016Ashraf AmanullahVPBuy11,000$2.25$24,750.0011,000View SEC Filing  
12/19/2016John MendleinCEOBuy69,000$2.20$151,800.00View SEC Filing  
12/16/2016Paul SchimmelDirectorBuy50,000$2.48$124,000.0040,440View SEC Filing  
5/11/2016Grove MatsuokaInsiderBuy12,412$3.04$37,732.482,412View SEC Filing  
4/14/2016Paul SchimmelDirectorBuy66,219$4.18$276,795.4253,012View SEC Filing  
4/13/2016Paul SchimmelDirectorBuy9,835$3.85$37,864.7520,412View SEC Filing  
4/12/2016Paul SchimmelDirectorBuy9,127$3.71$33,861.1720,412View SEC Filing  
4/11/2016Paul SchimmelDirectorBuy32,659$3.57$116,592.63214,931View SEC Filing  
4/8/2016Paul SchimmelDirectorBuy85,000$3.22$273,700.00187,572View SEC Filing  
4/7/2016Paul SchimmelDirectorBuy40,000$3.19$127,600.00102,572View SEC Filing  
4/6/2016Paul SchimmelDirectorBuy25,000$3.20$80,000.0062,572View SEC Filing  
4/5/2016John MendleinCEOBuy2,500$3.55$8,875.00248,471View SEC Filing  
4/5/2016Paul SchimmelDirectorBuy25,000$3.52$88,000.0037,572View SEC Filing  
5/12/2015James E FlynnInsiderBuy50,000$14.00$700,000.00View SEC Filing  
5/12/2015Sofinnova Venture Partners Ix,Major ShareholderBuy320,000$14.00$4,480,000.00View SEC Filing  
5/29/2013David C UprichardDirectorSell2,010$74.04$148,820.40View SEC Filing  
5/28/2013John A CottinghamInsiderSell60,000$74.03$4,441,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

aTyr Pharma (NASDAQ LIFE) News Headlines

Source:
DateHeadline
Insider Buying: aTyr Pharma, Inc. (LIFE) Director Acquires 150,000 Shares of StockInsider Buying: aTyr Pharma, Inc. (LIFE) Director Acquires 150,000 Shares of Stock
www.americanbankingnews.com - May 21 at 8:20 PM
aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 International ConferenceaTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 International Conference
finance.yahoo.com - May 17 at 9:16 AM
aTyr Pharma, Inc. (LIFE) Major Shareholder Sells $2,984,663.88 in StockaTyr Pharma, Inc. (LIFE) Major Shareholder Sells $2,984,663.88 in Stock
www.americanbankingnews.com - May 16 at 7:17 PM
William Blair Brokers Boost Earnings Estimates for aTyr Pharma, Inc. (LIFE)William Blair Brokers Boost Earnings Estimates for aTyr Pharma, Inc. (LIFE)
www.americanbankingnews.com - May 16 at 7:17 AM
Q2 2018 Earnings Forecast for aTyr Pharma, Inc. Issued By Piper Jaffray (LIFE)Q2 2018 Earnings Forecast for aTyr Pharma, Inc. Issued By Piper Jaffray (LIFE)
www.americanbankingnews.com - May 16 at 7:17 AM
UPDATE: Citi Downgrades aTyr Pharma (LIFE) to SellUPDATE: Citi Downgrades aTyr Pharma (LIFE) to Sell
www.streetinsider.com - May 15 at 9:32 AM
aTyr Pharma Cuts Workforce, And A Program Which Is Why I Would AvoidaTyr Pharma Cuts Workforce, And A Program Which Is Why I Would Avoid
seekingalpha.com - May 15 at 9:32 AM
Edited Transcript of LIFE earnings conference call or presentation 14-May-18 12:00pm GMTEdited Transcript of LIFE earnings conference call or presentation 14-May-18 12:00pm GMT
finance.yahoo.com - May 15 at 9:32 AM
aTyr Pharma (LIFE) Announces Quarterly  Earnings Results, Misses Expectations By $0.01 EPSaTyr Pharma (LIFE) Announces Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 15 at 8:13 AM
aTyr Pharma, Inc. (LIFE) Given Average Recommendation of "Hold" by BrokeragesaTyr Pharma, Inc. (LIFE) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 14 at 5:31 PM
aTyr Pharma (LIFE) Rating Lowered to Sell at CitigroupaTyr Pharma (LIFE) Rating Lowered to Sell at Citigroup
www.americanbankingnews.com - May 14 at 4:55 PM
aTyr Pharmas (LIFE) CEO Dr. Sanjay Shukla on Q1 2018 Results - Earnings Call TranscriptaTyr Pharma's (LIFE) CEO Dr. Sanjay Shukla on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 4:48 PM
Piper Jaffray Reaffirms Overweight Rating for aTyr Pharma (LIFE)Piper Jaffray Reaffirms Overweight Rating for aTyr Pharma (LIFE)
www.americanbankingnews.com - May 14 at 12:12 PM
aTyr Pharma (LIFE) Reports In-Line Q1 EPSaTyr Pharma (LIFE) Reports In-Line Q1 EPS
www.streetinsider.com - May 14 at 9:41 AM
Atyr Pharma: 1Q Earnings SnapshotAtyr Pharma: 1Q Earnings Snapshot
finance.yahoo.com - May 14 at 9:41 AM
aTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate RestructuringaTyr Pharma Announces First Quarter 2018 Operating Results, Program Prioritization and Corporate Restructuring
finance.yahoo.com - May 14 at 9:41 AM
aTyr Pharma to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 14, 2018aTyr Pharma to Host Conference Call and Webcast of First Quarter 2018 Financial Results on May 14, 2018
finance.yahoo.com - May 8 at 9:03 AM
 Brokerages Anticipate aTyr Pharma, Inc. (LIFE) to Announce -$0.35 Earnings Per Share Brokerages Anticipate aTyr Pharma, Inc. (LIFE) to Announce -$0.35 Earnings Per Share
www.americanbankingnews.com - May 6 at 3:18 PM
ValuEngine Upgrades aTyr Pharma (LIFE) to "Sell"ValuEngine Upgrades aTyr Pharma (LIFE) to "Sell"
www.americanbankingnews.com - May 3 at 12:39 AM
aTyr Pharma (LIFE) Set to Announce Quarterly Earnings on WednesdayaTyr Pharma (LIFE) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 2 at 3:50 AM
Q1 2018 EPS Estimates for aTyr Pharma, Inc. (LIFE) Boosted by AnalystQ1 2018 EPS Estimates for aTyr Pharma, Inc. (LIFE) Boosted by Analyst
www.americanbankingnews.com - April 20 at 7:10 AM
 Analysts Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.39 Earnings Per Share Analysts Expect aTyr Pharma, Inc. (LIFE) to Announce -$0.39 Earnings Per Share
www.americanbankingnews.com - April 19 at 3:10 PM
Eleven Biotherapeutics: Incredible Risk/Reward With A Catalyst ApproachingEleven Biotherapeutics: Incredible Risk/Reward With A Catalyst Approaching
seekingalpha.com - April 19 at 9:03 AM
aTyr Pharma (LIFE) Stock Rating Upgraded by Zacks Investment ResearchaTyr Pharma (LIFE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 18 at 9:42 PM
aTyr Pharma (LIFE) Cut to "Sell" at ValuEngineaTyr Pharma (LIFE) Cut to "Sell" at ValuEngine
www.americanbankingnews.com - April 14 at 8:35 PM
Zacks Investment Research Lowers aTyr Pharma (LIFE) to HoldZacks Investment Research Lowers aTyr Pharma (LIFE) to Hold
www.americanbankingnews.com - April 9 at 6:58 PM
aTyr Pharma (LIFE) Stock Rating Lowered by ValuEngineaTyr Pharma (LIFE) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 9 at 11:35 AM
aTyr Pharma (LIFE) Rating Increased to Buy at Zacks Investment ResearchaTyr Pharma (LIFE) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 9 at 11:02 AM
aTyr Pharma (LIFE) Stock Rating Lowered by Zacks Investment ResearchaTyr Pharma (LIFE) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 6 at 7:38 PM
Zacks: Analysts Anticipate aTyr Pharma Inc (LIFE) to Announce -$0.39 Earnings Per ShareZacks: Analysts Anticipate aTyr Pharma Inc (LIFE) to Announce -$0.39 Earnings Per Share
www.americanbankingnews.com - April 2 at 5:20 PM
aTyr Pharma (LIFE) Cut to "Hold" at Zacks Investment ResearchaTyr Pharma (LIFE) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 1:49 PM
aTyr Pharma, Inc. (LIFE) Sees Hammer Chart Pattern: Time to Buy?aTyr Pharma, Inc. (LIFE) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - March 26 at 9:27 AM
aTyr Pharma (LIFE) Upgraded by Zacks Investment Research to BuyaTyr Pharma (LIFE) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - March 24 at 7:20 PM
Zacks Investment Research Upgrades aTyr Pharma (LIFE) to BuyZacks Investment Research Upgrades aTyr Pharma (LIFE) to Buy
www.americanbankingnews.com - March 23 at 7:56 PM
William Blair Equities Analysts Lift Earnings Estimates for aTyr Pharma Inc (LIFE)William Blair Equities Analysts Lift Earnings Estimates for aTyr Pharma Inc (LIFE)
www.americanbankingnews.com - March 22 at 8:45 AM
aTyr Pharma Inc Expected to Earn Q1 2019 Earnings of ($0.37) Per Share (LIFE)aTyr Pharma Inc Expected to Earn Q1 2019 Earnings of ($0.37) Per Share (LIFE)
www.americanbankingnews.com - March 21 at 11:01 AM
Edited Transcript of LIFE earnings conference call or presentation 19-Mar-18 9:00pm GMTEdited Transcript of LIFE earnings conference call or presentation 19-Mar-18 9:00pm GMT
finance.yahoo.com - March 20 at 4:39 PM
aTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate UpdateaTyr Pharma Announces Fourth Quarter and Year-End 2017 Operating Results and Provides Corporate Update
globenewswire.com - March 20 at 9:18 AM
aTyr Pharma, Inc. to Host Earnings CallaTyr Pharma, Inc. to Host Earnings Call
finance.yahoo.com - March 20 at 9:18 AM
Are Big Pharma Using Corporate Tax Savings to Lower Drugs Costs?Are Big Pharma Using Corporate Tax Savings to Lower Drugs Costs?
www.zacks.com - March 10 at 9:08 AM
aTyr Pharma to Host Conference Call and Webcast of Full Year 2017 Financial Results on March 19, 2018aTyr Pharma to Host Conference Call and Webcast of Full Year 2017 Financial Results on March 19, 2018
finance.yahoo.com - March 7 at 9:14 AM
aTyr Pharma (LIFE) Scheduled to Post Quarterly Earnings on WednesdayaTyr Pharma (LIFE) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 7 at 2:14 AM
Contrasting aTyr Pharma (LIFE) and Oncomed Pharmaceuticals (OMED)Contrasting aTyr Pharma (LIFE) and Oncomed Pharmaceuticals (OMED)
www.americanbankingnews.com - March 4 at 5:18 PM
aTyr Pharma to Present at Two Upcoming Investor Conferences in MarchaTyr Pharma to Present at Two Upcoming Investor Conferences in March
finance.yahoo.com - March 1 at 8:53 AM
aTyr Pharma Inc (LIFE) Receives Average Recommendation of "Hold" from BrokeragesaTyr Pharma Inc (LIFE) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - March 1 at 5:30 AM
aTyr Pharma (LIFE) Rating Lowered to Hold at Zacks Investment ResearchaTyr Pharma (LIFE) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - February 24 at 9:48 PM
JPMorgan Chase & Co. Lowers aTyr Pharma (LIFE) to UnderweightJPMorgan Chase & Co. Lowers aTyr Pharma (LIFE) to Underweight
www.americanbankingnews.com - February 14 at 10:38 AM
Zacks: Analysts Anticipate aTyr Pharma, Inc. (LIFE) Will Announce Earnings of -$0.43 Per ShareZacks: Analysts Anticipate aTyr Pharma, Inc. (LIFE) Will Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - February 10 at 9:18 PM
Q1 2018 Earnings Forecast for aTyr Pharma, Inc. Issued By William Blair (LIFE)Q1 2018 Earnings Forecast for aTyr Pharma, Inc. Issued By William Blair (LIFE)
www.americanbankingnews.com - February 8 at 9:18 AM
Achieve Life Sciences (ACHV) vs. aTyr Pharma (LIFE) Head-To-Head AnalysisAchieve Life Sciences (ACHV) vs. aTyr Pharma (LIFE) Head-To-Head Analysis
www.americanbankingnews.com - February 5 at 11:14 PM

SEC Filings

aTyr Pharma (NASDAQ:LIFE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

aTyr Pharma (NASDAQ:LIFE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

aTyr Pharma (NASDAQ LIFE) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.